Status:
COMPLETED
The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia
Lead Sponsor:
North Suffolk Mental Health Association
Collaborating Sponsors:
Massachusetts General Hospital
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
It has been suggested that patients with schizophrenia smoke in order to produce amelioration of dysfunctional dopaminergic pathways allowing them to experience pleasure and satisfaction and overcome ...
Detailed Description
Heavy smoking continues to represent a significant public health problem for people in the general population and for people with major mental illness. Twenty-four percent of adults in the general pop...
Eligibility Criteria
Inclusion
- Schizophrenia group inclusion criteria:
- DSM IV diagnosis of schizophrenia with stable symptoms and a stable dose of antipsychotic medications for at least 4 weeks
- Age 18-55 inclusive
- Able to provide informed consent
- Self reported smoking of 20 or more cigarettes per day for at least 12 months
- FTND score of \>/= 5
- Expired air CO of \>/= 10 ppm
- WRAT-3 IQ score greater than or equal to 35
- Normal or corrected to normal vision
- Control group inclusion criteria: Same as above except for diagnosis of schizophrenia
Exclusion
- Schizophrenia Group exclusion criteria:
- Current unstable serious medical illness such as uncontrolled high blood pressure, untreated ischemic heart disease
- Use of any cholinesterase inhibitor such as galantamine in the past 3 months
- History of skin diseases (e.g., psoriasis), skin allergies, or strong reactions to topical preparations, medical dressings, tapes or nicotine patches
- Treated with an investigational medication in the last 30 days
- Currently or planning to become pregnant in the next 8 weeks as verified by positive pregnancy test or childbearing potential and not using adequate contraception
- Substance abuse in the past month: Self reported or diagnosed during chart review and verified by positive salivary test for cocaine, methamphetamine, amphetamine, ethanol, THC, opiates or PCP at screen
- Current major depressive disorder
- History of cognitive impairment due to other disorders such as head injury, dementia, general medical condition
- Diagnosis of mental retardation
- Control group exclusion criteria: Same as above except for diagnosis of schizophrenia or family history of psychiatric illness
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00373126
Start Date
April 1 2005
Last Update
May 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Freedom Trail Clinic, 25 Staniford Street
Boston, Massachusetts, United States, 02114